Recce Pharmaceuticals up 6% on new antibiotic production milestone
Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
SVR | Ann: Savor FY24 Earnings Guidance & Change in Banking Partner | 06:56 | 0 | 58 | |||
|
|||||||
SVR | Ann: Savor announces half year result | 28/11/23 | 0 | 86 | |||
|
|||||||
SVR | Ann: Savor half year results announcement date | 23/11/23 | 0 | 88 | |||
|
|||||||
SVR | Ann: D&O Ongoing Disclosure - Ryan Davis | 19/10/23 | 0 | 94 | |||
|
|||||||
SVR | Ann: SPH Notice - David Lyall Holdings Limited | 18/10/23 | 0 | 111 | |||
|
|||||||
SVR | Ann: SPH Notice - Jeremy & Rachel Blake & Brett Robin Gamble | 17/10/23 | 0 | 120 | |||
|
|||||||
SVR | Ann: Capital Change Notice | 16/10/23 | 0 | 99 | |||
|
|||||||
SVR | Ann: Capital Change Notice | 12/10/23 | 0 | 115 | |||
|
See All Discussions